脆性组氨酸三联体基因甲基化与前列腺癌的相关性及临床意义

Clinical significance and correlation of FHIT methylation in serum of prostate cancer

目的:检测前列腺癌患者血清中脆性组氨酸三联体基因(fragile histidine triad,FHIT)甲基化状态,探讨FHIT甲基化与前列腺癌患者临床病理特征及5年生化复发和临床进展之间的关系。方法:采用MSP法检测78例前列腺癌和45例前列腺增生患者血清中FHIT甲基化表达状态,分析FHIT甲基化率与前列腺癌患者临床病理的关系,采用Kaplan-Meier生存分析FHIT甲基化率与前列腺癌5年生化复发和5年临床进展之间的关系。结果:前列腺癌患者血清中FHIT基因甲基化率为48.72%,高于前列腺增生患者的4.44%,差异有显著意义(PP<0.05)。FHIT甲基化与前列腺癌患者年龄、术前前列腺特异抗原(PSA)、TNM分期、Gleason分级有关;在前列腺癌Gleason分级≤7和Gleason 8~10分级中,FHIT甲基化率分别为59.18%和31.03%,在Ⅰ~Ⅱ期和Ⅲ~Ⅳ期前列腺癌患者中,FHIT甲基化率分别为37.50%和66.67%,差异有统计学意义(P<0.05)。甲基化组5年复发率和5年累计临床进展率高于非甲基化组(P<0.05)。结论:FHIT甲基化与前列腺癌临床病理有关,检测FHIT甲基化状态有助于评估前列腺癌患者的临床预后。

Objective To detect the methylation status of fragile histidine triad(FHIT)gene in the serum of patients with prostate cancer,and to explore the relationship between FHIT methylation and clinical pathology,5-year biochemical recurrence and clinical progression of prostate cancer.Methods The MSP method was used to detect FHIT gene methylation expression in the serum of 78 patients with prostate cancer and 45 patients with benign prostate hyperplasia.To analyze the relationship between FHIT methylation rate and clinical pathology of patients with prostate cancer,as well as the relationship between 5-year biochemical recurrence and 5-year clinical progression of prostate cancer in Kaplan Meier survival analysis.Results The methylation rate of FHIT gene in the serum of prostate cancer patients was 48.72%,the methylation rate of FHIT gene in the serum of patients with benign prostatic hyperplasia was 4.44%,and there was a significant difference between the two(P<0.05).FHIT methylation is associated with age,preoperative PSA,TNM staging,and Gleason grading in prostate cancer patients;The FHIT methylation rates in Gleason grade≤7 and Gleason grade 8-10 of prostate cancer were 59.18%and 31.03%,respectively.The FHIT methylation rates in stages I-II and III-IV were 37.50%and 66.67%,respectively,with significant differences(P<0.05).FHIT methylation was higher in patients with 5-year biochemical recurrence and clinical progression of prostate cancer than in no biochemical recurrence and no clinical progression patients(P<0.05).Conclusion FHIT methylation is related to the clinical pathology of prostate cancer,and detecting FHIT methylation status can help evaluate the clinical prognosis of prostate cancer patients.